Evidence of the Prognostic Value of Pretreatment Systemic Inflammation Response Index in Cancer Patients: A Pooled Analysis of 19 Cohort Studies.

Yi Zhang,Yang Wang,Fangteng Liu

doi:10.1155/2020/8854267

Abstract

Objective Systemic inflammation response index (SIRI) is a new inflammation-based evaluation system that has been reported for predicting survival in multiple tumors, but the prognostic significance of SIRI in cancers has not been evinced. Methods Eligible studies updated on December 31, 2019, were selected according to inclusion criteria, the literature searching was performed in PubMed, Web of Science, Google Scholar, and Cochrane. Hazard ratios (HRs), and 95% confidence intervals (CIs) were extracted and pooled by using Stata/SE 14.1. Results 11 publications involving 19 cohort studies with a total of 5,605 subjects were included. Meta-analysis results evinced that high SIRI was associated with worse OS (HR = 2.30, 95% CI: 1.87-2.83, p ≤ 0.001), poor CSS/DSS (HR = 2.83, 95% CI: 1.98-4.04, p ≤ 0.001), and inferior MFS/DFS/PFS/RFS/TTP (HR = 1.88, 95% CI: 1.65-2.15, p ≤ 0.001). The association of SIRI with OS was not significantly affected when stratified by diverse confounding factors. It was suggested that tumor patients with high pretreatment SIRI levels would suffer from adverse outcomes. Conclusion High SIRI is associated with unfavorable clinical outcomes in human malignancies; pretreatment SIRI level might be a useful and promising predictive indicator of prognosis in cancers.

Highlights

In recent years, despite the great progress that has been made in diagnosis and treatment technologies and strategies [1], most patients with malignancy remain at risk for recurrence or metastasis and had a short survival
This study reported that Systemic inflammation response index (SIRI) was a noninvasive and simple tool for predicting the survival of patients with advanced pancreatic cancer, and SIRI could be useful to monitor the status of the local immune response and systemic inflammation in patients [5]
cancer-specific survival (CSS) was available in 4 cohort studies from two papers with 1115 patients; the results showed that SIRI level was negatively correlated with a poor CSS (HR = 3:64, 95% confidence intervals (CIs): 2.48-5.34, p ≤ 0:001); disease-specific survival (DSS) was only available in 2 cohorts from one paper with 782 patients; a significant association was found between SIRI and DSS (HR = 1:99, 95% CI: 1.46-2.72, p ≤ 0:001)

Summary

Introduction

Despite the great progress that has been made in diagnosis and treatment technologies and strategies [1], most patients with malignancy remain at risk for recurrence or metastasis and had a short survival. To predict the prognosis of cancer patients, using inflammation-related parameters could be a good molecular-based strategy. Short for SIRI, is a newly developed inflammation-related biomarker. It is based on three common inflammation-related parameters: peripheral neutrophil, monocyte, and lymphocyte counts, and calculated as follows: neutrophils × monocytes/. This study reported that SIRI was a noninvasive and simple tool for predicting the survival of patients with advanced pancreatic cancer, and SIRI could be useful to monitor the status of the local immune response and systemic inflammation in patients [5]

Methods

Results

Conclusion